Genzyme completes sale of diagnostic products biz; Scientists develop artificial pancreas for pregnant women;

> Genzyme has completed the sale of its diagnostic products business to Sekisui Chemical $265 million in cash. Genzyme release

> Scientists have developed an "artificial pancreas" to cut dramatically the risks for pregnant women with diabetes. The device, which is worn on the side of the body, helps to keep blood sugar levels under control and prevent the potentially fatal complications that can affect women with insulin-dependent diabetes during their pregnancy. Report

> Boston Scientific has received FDA approval for its Renegade HI-FLOFathom Pre-Loaded System for selective access and delivery of diagnostic, embolic and therapeutic materials into the peripheral vasculature. The system will primarily be used by interventional radiologists for minimally invasive procedures to treat uterine fibroids and liver cancer. The company said it plans to launch the product immediately in the U.S. Boston Scientific release

> NDI has launched the NDI Healthcare Fund, a new commercialization fund focused on developing innovative neurodevice technologies. The Fund recently raised $8 million from equity investments and a grant from the State of Ohio. NDI release

> Sunshine Heart has announced that Paul Buckman, chairman and chief executive officer of Pathway Medical Technologies, has been appointed to the company's board as a non-executive director. Sunshine Heart release

> ICU Medical, a San Clemente, CA medical devicemaker, on Monday reported fourth-quarter results that surpassed Wall Street's expectations, sending its shares soaring in afterhours trading. Article

> Quest Diagnostics said it will repurchase 15.4 million shares of its common stock from GlaxoSmithKline, about half of the London-based drugmaker's holdings in the laboratory testing company. Item

> Urological catheterization company PercuVision has been awarded a $1.4 million commercialization loan by the Ohio Department of Development. News

And Finally... A dog trained to sniff out colorectal cancer was almost as accurate as a colonoscopy in a study that suggests less invasive tests for the disease may be developed. The Labrador retriever was at least 95 percent as accurate as colonoscopy when smelling breath samples, and 98 percent correct with stool samples, according to the study, published today in the medical journal Gut. News

Suggested Articles

Testing company LumiraDx is selling its pandemic virus rapid test across the U.K. targeting individuals without any COVID-19 symptoms.

The FDA has given genomics firm Helix a wider emergency use authorization for its pandemic test.

Celltrion has nabbed a speedy preapproval for its quick pandemic virus test as it forecasts high demand.